跳至主要内容
临床试验/NCT00081042
NCT00081042已完成2 期

An Open-Label, Multicenter, Phase II Trial of ABI-007 (A Cremophor® -Free, Protein Stabilized, Nanoparticle Paclitaxel) in Previously Treated Patients With Metastatic Melanoma

Jonsson Comprehensive Cancer Center2 个研究点 分布在 1 个国家开始时间: 2004年2月最近更新:
适应症
相关药物

试验速览

阶段
2 期
状态
已完成
试验地点
2

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: This phase II trial is studying how well ABI-007 works in treating patients with inoperable (unresectable) locally recurrent or metastatic melanoma.

详细描述

OBJECTIVES:

Primary

  • Determine the antitumor activity of ABI-007 in patients with inoperable locally recurrent or metastatic melanoma.
  • Determine the safety and tolerability of this drug in these patients.

Secondary

  • Determine the time to disease progression, in terms of the rate and duration of response or stable disease, in patients treated with this drug.
  • Determine the survival of patients treated with this drug.
  • Determine the effects of this drug on biomarkers of melanoma in these patients.
  • Correlate biomarker levels with response in patients treated with this drug.

研究设计

研究类型
Interventional
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验